

## DAFTAR PUSTAKA

- Agustin, O. A., & Fitriyaningsih. (2020). Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan Di Apotek X Jambi. *Electronic Journal E-SEHAD*, 1(1), 1–10. <https://online-journal.unja.ac.id/e-sehad/article/view/10759>.
- Cascorbi, I. (2012). *Drug Interactions Principles, Examples and Clinical Consequences*. *Deutsches Arzteblatt International*, 109(33–34), 546–556. <https://doi.org/10.3238/arztebl.2012.0546>.
- Chalik, Raimundus. 2016. *Anatomi Fisiologi Manusia*. Jakarta: Kementerian Kesehatan Republik Indonesia. Retrieved from: <http://bppsdmk.kemkes.go.id/pusdiksdmk/wp-content/uploads/2017/08/Anatomi-dan-Fisiologi-Manusia-Komprehensif.pdf>.
- Chaudhry, S. (2012). *Chronic kidney disease (CKD) | McMaster Pathophysiology Review*. Diakses tanggal 30 Oktober 2022, from <http://www.pathophys.org/ckd/>.
- Dipiro, J. T. (2021). *Pharmacotherapy: A Pathophysiologic Approach Eleventh Edition*. The Mc Graw Hill: United States.
- Drugs.com. (2023). *Drug Interaction Checker*. Diakses pada 13 April 2023, dari [https://www.drugs.com/drug\\_interactions.html](https://www.drugs.com/drug_interactions.html).
- Gabay, B. M., Pharm, D., Spencer, S. H., & Pharm, D. (2021). *Drug Interactions: Scientific and Clinical Principles*. *Chronic Conditions and Public Health*, 7–28.
- Hakim, L. N. (2020). Urgensi Revisi Undang-Undang tentang Kesejahteraan Lanjut Usia. *Aspirasi: Jurnal Masalah-Masalah Sosial*, 11(1), 43–55. <https://doi.org/10.46807/aspirasi.v11i1.1589>.
- Halli-Tierney, A. D., Scarbrough, C., & Carroll, D. (2019). *Polypharmacy: Evaluating Risks and Deprescribing*. *American family physician*, 100(1), 32–38.
- ICD-10. 2019. *International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version*. Diakses pada 13 April 2023, dari <https://icd.who.int/browse10/2019/en#/X>.
- Kang, Y. U., Kim, H. Y., Choi, J. S., Kim, C. S., Bae, E. H., Ma, S. K., & Kim, S. W. (2014). *Metabolic Syndrome and Chronic Kidney Disease in an Adult Korean Population: Results from the Korean National Health Screening*. *PLoS ONE*, 9(5), e93795. <https://doi.org/10.1371/journal.pone.0093795>.

- Kemendes RI. (2018). Hasil Riset Kesehatan Dasar Tahun 2018. Kementerian Kesehatan RI, 53(9), 1689–1699.
- Kementerian Kesehatan RI. 2021. Profil Kesehatan Indonesia Tahun 2020 (ISBN 978-623-301-218-8). Jakarta: Kementerian Kesehatan RI. Diakses dari: <https://www.kemkes.go.id/downloads/resources/download/pusdatin/profil-kesehatan-indonesia/Profil-Kesehatan-Indonesia-Tahun-2020.pdf>.
- Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: An update 2022. *Kidney International Supplements*, 12(1), 7. <https://doi.org/10.1016/j.kisu.2021.11.003>.
- Lubis, A. R., Tarigan, R. R., Nasution, B. R., Ramadani, S., & Vegas, A. (2016). Pedoman Penatalaksanaan Gagal Ginjal Kronik. *Divisi Nefrologi- Hipertensi Departemen Ilmu Penyakit Dalam*, 1–31.
- MacRae, C., Mercer, S. W., Guthrie, B., & Henderson, D. (2021). Comorbidity in chronic kidney disease: A large cross-sectional study of prevalence in Scottish primary care. *British Journal of General Practice*, 71(704), e243–e249. <https://doi.org/10.3399/bjgp20X714125>.
- Matzke GR, Aronoff GR, Jr AJA, Bennett WM, Decker BS, Eckardt K, et al. (2012). *Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease*. *Kidney inter., Suppl.* 2013; 3: 1–150.
- Medscape. (2023). *Drug Interaction Checker*. Diakses pada 13 April 2023, dari <https://reference.medscape.com/drug-interactionchecker>.
- Olumuyiwa, Jf., Akinwumi, Aa., Oluseyi, A., Oluwole, Ba., & Okaka, Ei. (2017). *Prevalence and pattern of potential drug-drug interactions among chronic kidney disease patients in south-western Nigeria*. *Nigerian Postgraduate Medical Journal*, 24(2), 88. [https://doi.org/10.4103/npmj.npmj\\_64\\_17](https://doi.org/10.4103/npmj.npmj_64_17).
- Saleem, A., Masood, I., & Khan, T. M. (2017). *Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: Results from a retrospective analysis*. *Integrated Pharmacy Research & Practice*, 6, 71–77. <https://doi.org/10.2147/IPRP.S128816>.
- Shahzadi, A., Sonmez, I., Kose, C., Oktan, B., Alagoz, S., Sonmez, H., Hussain, A., & Akkan, A. G. (2022). *The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit*. *Medicina (Lithuania)*, 58(2), 1–10. <https://doi.org/10.3390/medicina58020183>.

Snyder, B. D., Polasek, T. M., & Doogue, M. P. (2012). *Drug interactions: Principles and practice*. *Australian Prescriber*, 35(3), 85–88. <https://doi.org/10.18773/austprescr.2012.037>.

Tyrer, P. (2017). *Comorbidity, consanguinity and co-occurrence*. *BJPsych Advances*, 23(3), 167–168. <https://doi.org/10.1192/apt.bp.116.016444>.

